Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

reast to distant sites in the body.  

Anthracyclines and taxanes (AT) are the most active and widely used chemotherapeutic agents for breast cancer, but the increased use of these agents at an early stage of disease often renders tumors resistant to these drugs by the time the disease recurs, thereby reducing the number of treatment options for metastatic disease.  Drugs used to treat patients who progress following AT treatment can be as high as 20-30%; however, resistance develops rapidly and new agents with different mechanisms of action, such as topoisomerase I inhibitors, are needed to allow novel ways to overcome the problem of drug resistance.(2)  There are currently no FDA-approved topoisomerase I inhibitors to treat breast cancer.

About NKTR-102 Nektar is developing NKTR-102, a topoisomerase I inhibitor-polymer conjugate with reduced peak concentrations and a continuous concentration profile.  NKTR-102 was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.  

In addition to the fully-enrolled Phase 2 studies in platinum-refractory/resistant ovarian cancer and metastatic breast cancer, NKTR-102 is also being tested in a separate Phase 2 clinical trial in patients with second-line colorectal cancer and a Phase 1 clinical trial evaluating NKTR-102 in combination with 5-FU therapy.  An expansion arm of the Phase 2 study of single-agent NKTR-102 in platinum-refractory/resistant ovarian cancer in women who failed prior Doxil therapy is also currently enrolling.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for leading biopharmaceutical
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014  Newport Corporation ... Siddhartha Kadia, Ph.D. has joined the company,s Board ... Executive Officer and a director of Evans Analytical ... testing, evaluation and analytical services to companies in ... Prior to joining Evans Analytical Group, Dr. Kadia ...
(Date:12/19/2014)... 19, 2014   Hospira, Inc. (NYSE: ... drugs and infusion technologies, today announced that the company ... Conference on Wednesday, Jan. 14, 2015, in San ... begin at 10:30 a.m. Pacific time on Wednesday, Jan. ... parties through a live audiocast accessible via the Investor ...
(Date:12/19/2014)... SAN DIEGO and CARDIFF-BY-THE-SEA, ... Therapeutics, Inc. (NASDAQ: SRNE ;  Sorrento), ... and associated pain, and Conkwest, Inc., a privately-held ... a Natural Killer (NK) cell-line based therapy, announced ... definitive agreement to jointly develop next generation CAR-TNK™ ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
... Corp. has signed a consent decree agreeing to correct manufacturing quality violations at its ... $175 million in unlawful profits from the sale of products that were ... , , ... , , ...
... ExpertRECALL, the leader in the field of recall logistics and ... recall logistics management in the food, drug and consumer products industries to ... with Michaels Stores, Inc. , ... Upon completion of their studies at Saint Louis University ,s ...
Cached Medicine Technology:Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3ExpertRECALL Awards First Scholarships for Product-Safety Education 2
(Date:12/20/2014)... 20, 2014 An improving macroeconomic landscape ... benefited the Massage Services industry over the ... industry products, the anticipated 1.0% annualized increase in per ... consumers with the means to afford additional massages. “While ... massage in a given year has declined from 2009 ...
(Date:12/20/2014)... The holidays can be anything but joyous for people ... candles and other allergy triggers. "The dust from ... packed away in dank basements or dusty attics is ... Rachna Shah, an affiliate faculty member at Loyola University ... release. Shah, who is also an allergist at ...
(Date:12/20/2014)... York (PRWEB) December 20, 2014 ... to move forward in U.S. courts, Bernstein Liebhard ... which suggests that children treated with the medication ... linked to breast development and lactation. The study, ... 34 children and adolescents who began treatment with ...
(Date:12/20/2014)... December 20, 2014 Developers of ... of a new plugin for Final Cut Pro X ... “TranSlice Volume 5 allows users to create hand drawn ... Said Christina Austin, CEO of Pixel Film Studios. “TranSlice ... professionalism while maintaining an easy to use interface.” , ...
(Date:12/20/2014)... 2014 Today, Balfleet.com, one of the ... Sale, offering 50%-70% off on its Mother of ... The mother of the bride dresses from Balfleet.com feature ... 24/7 accessible and takes pride in providing high quality ... are offering great discounts on our mother of the ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2
... Pharmaceuticals (Nasdaq: ENDP ) announced today that it ... by its wholly owned subsidiary, BTB Purchaser Inc., for all ... Inc. (Nasdaq: IDEV ). The subsequent offering ... time on Friday, March 13, 2009. American Stock Transfer ...
... in the World Available with Levemir(R), NovoLog(R) and NovoLog(R) ... Novo Nordisk has redesigned FlexPen(R), the number one ... diabetes patients to use less force when pushing the ... insulin with prominent color branding. FlexPen(R) is only available ...
... Protection Week March 1-7, 2009 FRAMINGHAM, Mass., March 2 ... the largest increase occurring at corporations and small businesses. ... that 86 percent of data breaches could be prevented, ... Protection Program ( www.identityforce.com/MPP ) in honor of National ...
... Washington, Will Her High-Tax Tendencies Decimate The ... NEW TAXES, OBAMA ANNOUNCES SEBELIUS AS HHS ... released today by the Republican National Committee: ... President Obama Will Make A Formal Announcement ...
... Matchmaker Software Expected to Accelerate Kidney Paired Donations and ... Waiting for Kidney TransplantsPALM DESERT, Calif., March 2 ... its Kidney Paired Donation software, Silverstone Matchmaker, at the ... use by California Pacific Medical Center (CPMC - San ...
... - In discussions with lenders to restructure debt -MCLEAN, Va., ... SRZ ) today reported financial results and operating data for ... host a conference call and webcast Monday, March 2, 2009, ... , "Championing quality of life for seniors has ...
Cached Medicine News:Health News:Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals 2Health News:Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals 3Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 2Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 3Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 4Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 5Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 6Health News:Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S. 7Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 2Health News:New Certification Seal Identifies Merchants Committed to Fighting Identity Theft 3Health News:RNC: Wrong Prescription 2Health News:RNC: Wrong Prescription 3Health News:RNC: Wrong Prescription 4Health News:RNC: Wrong Prescription 5Health News:RNC: Wrong Prescription 6Health News:Silverstone Solutions Launches New Version of Kidney Paired Donation Software at DEMO 2009 2Health News:Silverstone Solutions Launches New Version of Kidney Paired Donation Software at DEMO 2009 3Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 2Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 3Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 4Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 5Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 6Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 7Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 8Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 9Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 10Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 11Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 12Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 13Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 14Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 15Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 16Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 17Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 18Health News:Sunrise Reports Financial Results for Fourth Quarter and Full-Year 2008 19
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: